OTCMKTS:IPSEY Ipsen (IPSEY) Stock Price, News & Analysis $28.30 +0.41 (+1.47%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$28.30▼$28.3050-Day Range$27.89▼$33.7052-Week Range$26.97▼$34.34Volume344 shsAverage Volume490 shsMarket CapitalizationN/AP/E RatioN/ADividend Yield0.74%Price TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartDividendHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartDividendHeadlinesShort Interest Get Ipsen alerts: Email Address Ad WealthPressThis TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.But I can promise that you’ll see all the details for yourself here. About Ipsen Stock (OTCMKTS:IPSEY)Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.Read More IPSEY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IPSEY Stock News HeadlinesJuly 25 at 8:30 PM | ca.finance.yahoo.comIpsen S.A. (0MH6.IL)July 25 at 8:30 PM | msn.comIpsen S.A. Non-GAAP EPS of €4.78, revenue of €1.66B; raises FY24 outlookJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 25 at 8:18 AM | globenewswire.comIpsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024)July 24 at 7:12 AM | americanbankingnews.comIpsen (OTCMKTS:IPSEY) Shares Cross Above 200 Day Moving Average of $30.06May 28, 2024 | globenewswire.comAnnual General Meeting of Ipsen S.A. held on 28 May 2024May 28, 2024 | globenewswire.comDescription of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at Ipsen S.A.'s Annual General Meeting on 28 May 2024May 7, 2024 | globenewswire.comIpsen S.A. - Formalities for making available and consulting preparatory documents to the 2024 Annual General MeetingJuly 27, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.May 2, 2024 | finance.yahoo.comIpsen appoints Keira Driansky as EVP, President of North AmericaApril 24, 2024 | msn.comIpsen S.A. reports Q1 results; reaffirms full-year guidanceApril 24, 2024 | markets.businessinsider.comIpsen Q1 Total-sales Up 13.3% At CER; Confirms 2024 Financial GuidanceApril 24, 2024 | finance.yahoo.comIpsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidanceApril 23, 2024 | finanznachrichten.deIpsen Pharma: Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseasesApril 22, 2024 | markets.businessinsider.comIpsen, Skyhawk Therapeutics To Develop RNA-Modulating Molecules For Rare Neurological DisordersApril 17, 2024 | finance.yahoo.comIpsen publishes its 2023 Universal Registration DocumentApril 5, 2024 | seekingalpha.comIpsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For InvestorsApril 2, 2024 | finance.yahoo.comMarengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with IpsenSee More Headlines Receive IPSEY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ipsen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today7/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolOTCMKTS:IPSEY CUSIPN/A CIKN/A Webwww.ipsen.com Phone(315) 833-5000Fax33-01-58-33-50-01Employees5,300Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.17 Quick Ratio0.99 Sales & Book Value Annual Sales$3.58 billion Price / SalesN/A Cash Flow$3.56 per share Price / Cash Flow7.94 Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.96 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. David Loew (Age 57)MD, CEO & Director Comp: $2.3MMr. Aymeric Le Chatelier (Age 55)Executive VP & CFO Comp: $795.09kDr. Aidan Murphy Ph.D. (Age 58)Executive VP and Head of Technical Operations Mr. Craig MarksVice-President of Investor RelationsMr. Francois Garnier (Age 62)Executive VP of Legal Affairs, General Counsel & Chief Business Ethics Officer Ms. Gwenan WhiteExecutive VP and Head of Communications, Public Affairs & SustainabilityMr. Regis Mulot (Age 58)Executive VP & Chief Human Resources Officer Ms. Dominique Bery (Age 53)Head of Nordics & Baltics Mr. Bartosz Bednarz D.D.S.Executive VP and Head of Global Product & Portfolio StrategyMr. Philippe Lopes-Fernandes CBOExecutive VP & Chief Business OfficerMore ExecutivesKey CompetitorsBG MedicineOTCMKTS:BGMDGlobal WholeHealth PartnersOTCMKTS:GWHPHemagen DiagnosticsOTCMKTS:HMGNResponse GeneticsOTCMKTS:RGDXQIDEXX LaboratoriesNASDAQ:IDXXView All Competitors IPSEY Stock Analysis - Frequently Asked Questions How have IPSEY shares performed this year? Ipsen's stock was trading at $29.48 at the beginning of the year. Since then, IPSEY shares have decreased by 4.0% and is now trading at $28.2950. View the best growth stocks for 2024 here. How do I buy shares of Ipsen? Shares of IPSEY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:IPSEY) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ipsen S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ipsen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
